Lauren E. Ethridge
Assistant Professor, Psychology and Pediatrics Dale Hall Tower 739 405-325-4497 ethri at ou dot edu https://babl.oucreate.com// Ph.D., Neuroscience, University of Georgia, 2011RESEARCH:
The Brain and Biomarker Laboratory, under the direction of Dr. Lauren Ethridge, is a multidisciplinary, translational neuroscience laboratory focusing on applications of basic science to clinical outcomes, particularly in neurodevelopmental disorders.
The BABL group centers on the use of dense-array EEG as a translational tool for learning more about brain function in neurodevelopmental disorders. The ultimate goal of our research is to establish non-invasive biological markers for changes in brain function that not only elucidate neural and molecular pathways affected by disorders such as Autism Spectrum Disorder but also serve as aids for early identification, early predictors for response to individualized treatment protocols, and reliable indicators of treatment effects.
Research in the lab is highly collaborative, with a large network of investigators across the country. Current research includes:
1. EEG as a translational, treatment sensitive, biomarker in rare genetic disorders associated with autism, including Fragile X Syndrome and Phelan-McDermid Syndrome
2. Neural correlates of face processing in toddlers at risk for autism
3. Characteristics of EEG activity related to variation in ASD symptoms across the full spectrum, including subclinical characteristics in the typically developing population
4. Dense phenotyping of biologically based subtypes (“biotypes”) across the schizo-bipolar spectrum of psychosis
Selected Publications:
Norris, J. E., Schmitt, L. M., De Stefano, L. A., Pedapati, E. V., Erickson, C. A., Sweeney, J. A., & Ethridge, L. E. (2023) Neuropsychiatric feature-based subgrouping reveals neural sensory processing spectrum in female FMR1 premutation carriers: A pilot study. Frontiers in Integrative Neuroscience 17:2.
Norris, J. E., De Stefano, L. A., Schmitt, L. M., Pedapati, E. V., Erickson, C. A., Sweeney, J. A., & Ethridge, L. E. (2022) Hemispheric utilization of alpha oscillatory dynamics as a unique biomarker of neural compensation in females with fragile X syndrome. ACS Chemical Neuroscience 13(23): 3389-3402.
Rosen, A. F. G., Auger, E., Woodruff, N., Mado Proverbio, A., Song, H., Ethridge, L. E. & Bard, D. (2022) The multiple indicator multiple cause model for cognitive neuroscience: An analytic tool which emphasizes the behavior in brain-behavior relationships. Frontiers in Psychology 13: 943613.
Schmitt, L. M., Dominick, K. C., Liu, R., Pedapati, E. V., Ethridge, L. E., Smith, E., Sweeney, J. A., & Erickson, C. A. (2022) Evidence for three subgroups of female FMR1 premutation carriers defined by distinct neuropsychiatric features: A pilot study. Frontiers in Integrative Neuroscience 15: 797546.
Auger, E., Berry-Kravis, E., & Ethridge, L. E. (2022) Independent evaluation of the Harvard automated processing pipeline for Electroencephalography 1.0 using multi-site EEG data from children with Fragile X Syndrome. Journal of Neuroscience Methods 37: 109501.
Bell, K., McMillin, K., & Ethridge, L. E. (2022) Bereft and Left: The interplay between insecure attachment, isolation, and neurobiology. Developmental Review 64: 101020.
Norris, L. E., Kimball, S. H., Nemri, D. C., & Ethridge, L. E. (2022) Toward a multidimensional understanding of misophonia using cluster-based phenotyping. Frontiers in Neuroscience: 16:832516.
Jonak, C. R., Pedapati, E. V., Schmitt, L. M., Assad, S. A., Sandhu, M. S., De Stefano, L. A., Ethridge, L. E., Razak, K. A., Sweeney, J. A., Binder, D. K., & Erickson, C. A. (2022) Baclofen-associated neurophysiologic target engagement across species in fragile x syndrome. Journal of Neurodevelopmental Disorders 14(1): 1-15.
Pedapati, E., Schmitt, L., Liu, R., Ethridge, L., Smith, E., Sweeney, J., Shaffer, R., Dominick, K., Gilbert, D., Wu, S., Horn, P., Binder, D., Lamy, M., Axford, M., Miyakoshi, M., and Erickson, C. (2021) Neocortical localization and thalamocortical modulation of neuronal hyperexcitability in Fragile X Syndrome. Communications Biology 5(1): 442.
Berry-Kravis, E. M., Harnett, M. D., Reines, S. A., Reese, M. A., Ethridge, L. E. Outterson, A. H., Michalak, C., Furman, J., and Gurney, M. (2021) Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Nature Medicine 27: 862-870.